Telemedicine and Social Media for People Who Inject Drugs (PWID) in Greece

Sponsor
State University of New York at Buffalo (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05794984
Collaborator
Hellenic Scientific Society for the Study of AIDS, Sexually Transmitted and Emerging Diseases (Other)
210
8

Study Details

Study Description

Brief Summary

The current study seeks to address questions regarding internet and social media usage as well as telemedicine concept and knowledge, by conducting targeted focus group discussions (FGDs) and administering cross-sectional questionnaires among PWID in Greece. Further parameters, such as perceptions for high-quality healthcare access, confidentiality, privacy, and security, will also be explored.

Condition or Disease Intervention/Treatment Phase
  • Other: Focus group discussions and survey questionnaire

Detailed Description

The study's aim is to access the feasibility, acceptability and accessibility of social media and telemedicine as methods to obtain healthcare, in order to improve linkage-to-care among Greek substance users. Underserved populations, such as people who inject drugs (PWID) have limited access to healthcare and a potential solution to expanding healthcare access points is telemedicine. For the past decade, we have investigated the efficacy of a facilitated telemedicine model for hepatitis C virus (HCV) treatment integrated into opioid treatment programs (OTPs) for PWIDs. We have achieved high rates of HCV resolution and high patient-satisfaction through facilitated telemedicine. We now seek to explore whether this same intervention might be feasible and acceptable in Greece. The first step is to capture and explore the current knowledge, experiences, believes, perceptions and attitudes of PWID in Greece regarding internet and social media usage and telemedicine concept, through targeted Focus Group Discussions (FGDs) and administration of cross-sectional questionnaire. The perceptions for high-quality healthcare, confidentiality, privacy and security matters will also be explored as well as further relevant attributes.

Study Design

Study Type:
Observational
Anticipated Enrollment :
210 participants
Observational Model:
Other
Time Perspective:
Cross-Sectional
Official Title:
Targeted Focus Groups Discussions (FGDs) and Cross-sectional Questionnaire to Address Questions Regarding Telemedicine Concept and Knowledge, and Social Media Usage Among People Who Inject Drugs (PWID) in Greece
Anticipated Study Start Date :
May 1, 2023
Anticipated Primary Completion Date :
Oct 1, 2023
Anticipated Study Completion Date :
Dec 31, 2023

Arms and Interventions

Arm Intervention/Treatment
Targeted Focus Group Discussions and Cross-sectional questionnaire

50 people for targeted Focus Group Discussions 160 people for Cross-sectional questionnaire

Other: Focus group discussions and survey questionnaire
Questions regarding internet and social media usage, as well as telemedicine concept and knowledge. Assessment of the feasibility, acceptability and accessibility of social media and telemedicine as methods to obtain healthcare. Perceptions for high-quality healthcare access, confidentiality, privacy, and security, will also be explored.

Outcome Measures

Primary Outcome Measures

  1. There are not specific predetermined endpoints to be defined. [For the FGDs approximately up to 3-4 months is needed to enroll all study subjects. For the cross-sectional questionnaire approximately up to 6-8 months is needed to enroll all study subjects. Endpoints will be generated according to study's results.]

    This is a mixed methods study designed to assess the feasibility, acceptability, and accessibility of telemedicine and social media to improve healthcare access among Greek PWUD. It is not an interventional trial. The results of this study will be used to generate endpoints and sample sizes for a larger trial.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Inclusion Criteria for the FDGs:
  • 18 years old

  • PWID

  • Willing and able to provide informed consent and participate

  • Fluent in Greek spoken language

  • Internet access

Inclusion Criteria for the cross-sectional questionnaire:
  • 18 years old

  • PWID

  • Willing and able to provide informed consent and participate

  • Fluent in Greek spoken language

Exclusion Criteria for FGD and cross-sectional questionnaire:
  • <18 years old

  • Unable/unwilling to consent

  • Legally incompetent

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • State University of New York at Buffalo
  • Hellenic Scientific Society for the Study of AIDS, Sexually Transmitted and Emerging Diseases

Investigators

  • Principal Investigator: Andrew Talal, MD, University at Buffalo

Study Documents (Full-Text)

None provided.

More Information

Additional Information:

Publications

Responsible Party:
Andrew Talal, Principal Investigator, State University of New York at Buffalo
ClinicalTrials.gov Identifier:
NCT05794984
Other Study ID Numbers:
  • STUDY00007088
First Posted:
Apr 3, 2023
Last Update Posted:
Apr 3, 2023
Last Verified:
Mar 1, 2023
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Apr 3, 2023